fingolimod
Showing 1 - 25 of 147
Intracerebral Hemorrhage Trial (Fingolimod)
Not yet recruiting
- Intracerebral Hemorrhage
- Fingolimod
- (no location specified)
Oct 17, 2023
Chemo-Induced Peripheral Neuropathy, Numbness, Pain Trial in Rochester, Columbus (Fingolimod, Fingolimod Hydrochloride,
Active, not recruiting
- Chemotherapy-Induced Peripheral Neuropathy
- +3 more
- Fingolimod
- +2 more
-
Rochester, Minnesota
- +1 more
Jan 17, 2023
Pharmacogenetics of Liver Toxicity in Multiple Sclerosis Treated
Recruiting
- Multiple Sclerosis
- Genetic polymorphism
- Measurement of fingolimod and fingolimod-phosphate concentrations
-
Caen, FranceCaen University Hospital
Aug 23, 2022
Breast Carcinoma Trial in Rochester, Columbus, Richmond (Fingolimod, Fingolimod Hydrochloride, Questionnaire Administration)
Active, not recruiting
- Breast Carcinoma
- Fingolimod
- +2 more
-
Rochester, Minnesota
- +2 more
Jul 6, 2022
Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection Trial in Houston (Fingolimod, Placebo)
Enrolling by invitation
- Interstitial Fibrosis
- +6 more
- Fingolimod
- Placebo
-
Houston, TexasHouston Methodist Research Institute
Jan 23, 2023
Multiple Sclerosis Trial in Clermont-Ferrand (Methylprednisolone, Placebo, natalizumab (NTZ))
Recruiting
- Multiple Sclerosis
- Methylprednisolone
- +3 more
-
Clermont-Ferrand, FranceCHU Clermont-Ferrand
Jan 5, 2023
Stroke Inflammation Trial in Fuzhou (Fingolimod)
Recruiting
- Stroke Inflammation
- Fingolimod
-
Fuzhou, ChinaThe First Affiliated Hospital of Fujian Medical University
Apr 12, 2022
Generic Fingolimod in Relapsing-Remitting Multiple Sclerosis in
Recruiting
- Relapsing-Remitting Multiple Sclerosis
- Fingolimod
-
Alexandria, Egypt
- +1 more
Jun 14, 2022
Diabetes, Type 2 Trial in Shenyang (Fingolimod, guideline-based treatment for DM)
Recruiting
- Diabetes Mellitus, Type 2
- Fingolimod
- guideline-based treatment for DM
-
Shenyang, ChinaDepartment of Neurology, General Hospital of Northern Theater Co
Mar 31, 2022
Intracerebral Hemorrhage, Cerebral Edema, Stroke Hemorrhagic Trial in Winston-Salem (Fingolimod 0.5 mg, Placebo, Standard of
Recruiting
- Intracerebral Hemorrhage
- +4 more
- Fingolimod 0.5 mg
- +2 more
-
Winston-Salem, North CarolinaWake Forest University Health Sciences
Nov 28, 2022
Impact of Fingolimod Adherence on Outcomes
Completed
- Multiple Sclerosis
- Fingolimod
-
East Hanover, New JerseyNovartis Investigational Site
Dec 15, 2021
Bioequivalence, Safety Trial in Mount-Royal (Fingolimod 0.5 mg capsules- Test drug)
Completed
- Bioequivalence
- Safety
- Fingolimod 0.5 mg capsules- Test drug
-
Mount-Royal, Quebec, CanadaAlgorithme Pharma Inc.
Dec 6, 2021
Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in
Completed
- Multiple Sclerosis
-
Aurora, ColoradoUniversity of Colorado Hospital
Mar 4, 2022
Czech Pharmaco-epidemiological Study on Disease Modifying Drugs
Completed
- Multiple Sclerosis
- interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
-
Prague, CzechiaIMPULS Endowment Fund
Mar 7, 2023
Relapsing Multiple Sclerosis (RMS) Trial in China (Fingolimod 0.5mg)
Recruiting
- Relapsing Multiple Sclerosis (RMS)
- Fingolimod 0.5mg
-
Beijing, Beijing, China
- +12 more
Feb 3, 2022
Stroke, Inflammation Trial in Hangzhou (Fingolimod)
Withdrawn
- Stroke
- Inflammation
- Fingolimod
-
Hangzhou, Zhejiang, ChinaThe second affiliated hospital of Zhejiang University
Jul 15, 2021
Relationship Between Oral DMT Burden and Adherence in MS
Enrolling by invitation
- Multiple Sclerosis
- Adherence, Medication
- Cladribine
- +5 more
-
Melbourne, Victoria, AustraliaMonash University
Aug 28, 2022
Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate
Recruiting
- Multiple Sclerosis
- Diroximel Fumarate
- +8 more
-
Eden Prairie, MinnesotaOptumInsight
Jan 9, 2023
Stroke, Inflammation Trial in Hangzhou (Fingolimod, Placebo)
Unknown status
- Stroke
- Inflammation
- Fingolimod
- Placebo
-
Hangzhou, Zhejiang, ChinaThe second affiliated hospital of Zhejiang University
Jul 17, 2021
Multiple Sclerosis (MS) Trial in Worldwide (Fingolimod, Ofatumumab, Siponimod)
Recruiting
- Multiple Sclerosis (MS)
- Fingolimod
- +5 more
-
Little Rock, Arkansas
- +55 more
Jan 13, 2023
Natural Killer Cells in Multiple Sclerosis Patients Treated With
Terminated
- Relapsing-Remitting Multiple Sclerosis
-
Berlin, GermanyCharité Universitätsmedizin Berlin
Jul 28, 2021
Stroke Trial (Fingolimod, )
Not yet recruiting
- Stroke
- Fingolimod
- placebo
- (no location specified)
Jan 17, 2021
Multiple Sclerosis, Relapsing-Remitting Trial in Washington (NeuroQuant, Automated Neuropsychological Assessment Matrices, EDSS)
Completed
- Multiple Sclerosis, Relapsing-Remitting
- NeuroQuant
- +3 more
-
Washington, District of ColumbiaThe George Washignton University
Jan 4, 2023
Coronavirus Disease (COVID-19) Trial in Fuzhou (Fingolimod 0.5 mg)
Withdrawn
- Coronavirus Disease (COVID-19)
- Fingolimod 0.5 mg
-
Fuzhou, ChinaWan-Jin Chen
Nov 11, 2020
Relapsing-remitting Multiple Sclerosis Trial in Stockholm (Rituximab)
Active, not recruiting
- Relapsing-remitting Multiple Sclerosis
-
Stockholm, SwedenFredrik Piehl
Apr 8, 2022